jcm-logo

Journal Browser

Journal Browser

Surgical Treatment for Lung Cancer—2nd Edition

A Special Issue of Journal of Clinical Medicine (ISSN 2077-0383) belonging to the section "Respiratory Medicine".

Deadline for manuscript submissions: 15 December 2026 | Viewed by 770

Editors


E-Mail Website
Guest Editor
Department of Thoracic Surgery, Poznan University of Medical Sciences, Szamarzewskiego 62 Street, 60-569 Poznan, Poland
Interests: lung cancer surgery; minimally invasive surgery; enhanced recovery after surgery; quality improvement; lung transplantation
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Thoracic Surgery, Poznan University of Medical Sciences, Szamarzewskiego 62 Street, 60-569 Poznan, Poland
Interests: mediastinal tumors; lung cancer; lung transplantation; minimally invasive surgery; multimodality treatment
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Thoracic Surgery, Poznan University of Medical Sciences, Szamarzewskiego 62 Street, 60-569 Poznan, Poland
Interests: lung cancer; lung transplantation; multimodality treatment; perioperative care
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of “Surgical Treatment for Lung Cancer” (https://www.mdpi.com/journal/jcm/special_issues/OCI9E8DS6I) and is being launched following the success of the first edition, which included five high-quality articles.

Despite significant progress, lung cancer remains a leading cause of cancer-related mortality worldwide. This Special Issue will explore advancements and ongoing challenges in the surgical treatment of lung cancer. Our aim is to showcase high-quality research that addresses current limitations and reimagines surgical practices to improve patient outcomes.

This Special Issue will cover a broad spectrum of topics, including, but not limited to, surgical techniques, perioperative care, and multimodality treatment. We will discuss minimally invasive surgery (video- and robotic-assisted thoracic surgery), the role, limitations, and technical advancements of segmental resections, and surgical treatment in advanced lung cancer. Additionally, we will focus on the role of Enhanced Recovery After Surgery (ERAS) protocols in preventing postoperative complications and the integration of immunotherapy with surgery to improve lung cancer treatment results. We encourage submissions that provide insights into overcoming core problems, such as the limitations of existing surgical methods and the effective combination of multimodal therapies. By bringing together leading experts and the latest research, this Special Issue will advance the standards of surgical care in lung cancer treatment and foster collaborations that lead to transformative clinical practices.

We invite researchers and clinicians to contribute original research articles and reviews that reflect the current state of the art and pave the way for future innovations in lung cancer surgery.

Dr. Piotr Gabryel
Dr. Cezary Piwkowski
Dr. Marek Ochman
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung cancer
  • surgery
  • minimally invasive surgery
  • immunotherapy
  • enhanced recovery after surgery
  • segmentectomy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

11 pages, 534 KB  
Review
Perioperative Systemic Therapies in Resectable Non-Small Cell Lung Cancer: Opportunities and Challenges
by Natalia Kwiatkowska, Alain Gelibter, Piotr Gabryel and Cezary Piwkowski
J. Clin. Med. 2026, 15(13), 5009; https://doi.org/10.3390/jcm15135009 - 27 Jun 2026
Viewed by 546
Abstract
Background/Objectives: Recent advancements in immunotherapy have significantly reduced recurrence rates and improved distant outcomes of patients with non-small cell lung cancer. This review synthesizes literature from 2020 to 2025, concentrating on preoperative immunotherapy outcomes. Methods: We analyzed treatment regimens, focusing on primary endpoints, [...] Read more.
Background/Objectives: Recent advancements in immunotherapy have significantly reduced recurrence rates and improved distant outcomes of patients with non-small cell lung cancer. This review synthesizes literature from 2020 to 2025, concentrating on preoperative immunotherapy outcomes. Methods: We analyzed treatment regimens, focusing on primary endpoints, the percentage of patients who underwent initial surgery, type of surgery, R0 rate, immune-related adverse events and chemotherapy-related toxicities as well as the rate of surgery delays and cancelations. Results: Our findings emphasize the importance of optimizing patient selection, effectively managing adverse events, and implementing strategies to minimize surgical delays and cancelations. Conclusions: We defined areas for improvement, such as increasing the implementation of minimally invasive surgeries and avoiding pneumonectomies. These priorities are essential for increasing the efficacy of immunotherapy in surgical settings for NSCLC, and improving patient outcomes. Full article
(This article belongs to the Special Issue Surgical Treatment for Lung Cancer—2nd Edition)
Show Figures

Graphical abstract

Back to TopTop